Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

Novel Combination Shows Promising Responses in Pancreatic Cancer

November 12th 2017

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

JCAR015 Experience Informs Future CAR-T Studies

November 11th 2017

The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.

Combinations Required to Further Advance Adoptive T-Cell Therapy

November 10th 2017

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

FDA Approves Letermovir for CMV Prophylaxis Post-Transplantation

November 9th 2017

The FDA has approved letermovir to prevent cytomegalovirus infection and disease in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant.

FDA Approves Vemurafenib for Rare Blood Cancer

November 6th 2017

The FDA has approved vemurafenib as a treatment for patients with Erdheim-Chester disease.

FDA Approval Sought for Frontline Brentuximab Vedotin for Hodgkin Lymphoma

November 3rd 2017

A supplemental new drug application has been submitted for brentuximab vedotin in combination with Adriamycin, vinblastine, dacarbazine as a frontline treatment for advanced classical Hodgkin lymphoma.

FDA Approves Acalabrutinib for Mantle Cell Lymphoma

October 31st 2017

The FDA has granted an accelerated approval to acalabrutinib as a treatment for adult patients with mantle cell lymphoma following at least 1 prior therapy.

Adjuvant Dabrafenib/Trametinib RFS Benefit Persists Across Melanoma Subgroups

October 21st 2017

A doubling in 3-year relapse-free survival rates remained consistent across patient subgroups treated with dabrafenib and trametinib, when compared with placebo, for patients with BRAF-mutant stage III melanoma.

Triplet Therapy on Horizon for BRAF+ Melanoma

October 20th 2017

The combination of anti–PD-1/PD-L1 immunotherapy with BRAF plus MEK inhibitors is advancing rapidly following early promising phase results for patients with BRAF-mutant advanced melanoma.

Early Study Shows Promise for Genetically Modified TILs in Advanced Melanoma

October 20th 2017

Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

October 19th 2017

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

Entrectinib Impresses for ROS1-Positive NSCLC

October 18th 2017

Treatment with entrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.

MET/EGFR Combo Effective for Advanced NSCLC

October 17th 2017

The combination of osimertinib and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non–small cell lung cancer.

Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC

October 16th 2017

A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non–small cell lung cancer.

FDA Accepts Lenvatinib Application for Advanced HCC

September 27th 2017

The FDA has accepted a supplemental new drug application for lenvatinib as a frontline systemic treatment for patients with advanced hepatocellular carcinoma.

Precision Medicine Moving Beyond HER2 in Breast Cancer

September 16th 2017

There is a significant transformation underway in the treatment of breast cancer as research advances and new laboratory techniques continue to shrink the so-called "undruggable genome."

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

September 15th 2017

A supplemental new drug application has been submitted for abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk men with castration-sensitive metastatic prostate cancer.

PROSTVAC Misses Phase III Goal in Prostate Cancer

September 15th 2017

PROSTVAC with or without GM-CSF was deemed unlikely to demonstrate an improvement in overall survival compared with placebo for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Frontline Dabrafenib/Trametinib Effective for BRAF+ NSCLC

September 11th 2017

Frontline treatment with the combination of dabrafenib and trametinib showed promising clinical efficacy for patients with BRAF-mutant metastatic non–small cell lung cancer.